Navigation Links
Medivation Presents Positive New Data on Dimebon's Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimer's Disease
Date:7/30/2008

-term benefits to Alzheimer's patients and provide further support for its potential as a promising therapeutic to treat this devastating disease."

Patients originally on placebo for 12 months who were then crossed over to Dimebon in the open-label extension phase stabilized across all key measures tested. Since these patients had declined over the previous 12 months while on placebo, they generally stabilized at a lower level of function than those treated with Dimebon for the full 18 months, suggesting a benefit of earlier treatment.

Dimebon Benefits Both Mild and Moderate Patients in 12-month Subgroup Analyses

New data from subgroup analyses by disease severity of the Dimebon double-blind placebo-controlled trial showed that Dimebon benefited both mild and moderate patients. In both mild and moderate patients, Dimebon treatment resulted in significant benefit on the study's primary endpoint, the Alzheimer's Disease Assessment Scale-cognition subscale, or ADAS-cog. The benefit in the moderate subpopulation was particularly robust, with a 9.7 point drug-placebo difference on the ADAS-cog (p<0.0001) after 12 months of treatment.

The subgroup analyses were presented in a separate poster presentation at ICAD 2008 by Rachelle Doody, M.D., Ph.D., the Effie Marie Cain Chair in Alzheimer's Disease Research at the Alzheimer's Disease and Memory Disorders Center, Baylor College of Medicine in Houston. "A nearly 10-point improvement over placebo in moderate patients on the ADAS-cog, a well-validated cognition scale in Alzheimer's disease, is unquestionably of clinical significance, especially in light of a clinical effect seen on the clinician's assessment of global function," said Dr. Doody. "If the results we saw for both the mild and moderate patients can be replicated, I believe that Dimebon will be an important advance in the treatment of Alzheimer's disease, regardless of stage."

Dimebon's Novel Mechanism of Action

In a podium
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
2. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
3. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
4. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
5. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
6. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
7. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
8. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
9. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
10. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
11. Anavex presents neuroprotective effects of Anavex 1-41 at the International Conference on Alzheimers Disease 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013   Nektar Therapeutics (Nasdaq: ... a human abuse liability (HAL) study for NKTR-181, ... entry into the brain.  This slow rate of entry is ... abuse of and addiction to current opioid analgesics. 1 ... was rated similar to placebo in "drug liking" and "feeling ...
(Date:6/19/2013)... Calif. , June 19, 2013 BD Biosciences, ... BDX ), a leading global medical technology company, today ... Analyzer , the latest in its line of high-performance research ... Analyzer delivers high-performance multicolor analysis with the most compact footprint ... 73.7 cm) and a height of 30" (76.2 cm). Recognizing ...
(Date:6/19/2013)... , June 19, 2013 NeuroDerm, ... study in volunteers, and preliminary results from a phase ... presented at the 2013 International Congress of Parkinson,s Disease ... drug formula under development for continuous administration through a ... plasma concentrations. ND0612 has been shown in ...
Breaking Medicine Technology:Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6
... 27, 2011 BioDrain Medical, Inc. (OTCBB: BIOR, OTCQB: ... automated surgical fluid disposal, today announced that it has ... underway at surgical facilities in Minnesota.  The Streamway System ... at both sites. Healthcare personnel trained in ...
... BEACH, Fla., June 27, 2011 Implementing an EHR system ... for a doctor that wants to attain Meaningful Use(1), but ... ongoing effort to assist doctors in their migration from paper ... three key services to Medical Messenger customers: ...
Cached Medicine Technology:BioDrain Streamway® System Receives Positive Evaluations on Two Additional Units 2BioDrain Streamway® System Receives Positive Evaluations on Two Additional Units 3Medical Messenger Partners With ComputerAssistant.com to Provide Key Elements of Meaningful Use Success 2
(Date:6/19/2013)... According to Transparency Market Research “Endoscopy ... Analysis and Forecast, 2011 – 2017,” the global endoscopy ... year 2011 and is expected to reach USD 10.8 ... from 2011 to 2017. Flexible endoscopes formed the largest ... 2,201 million for the year 2011. , Related Report ...
(Date:6/19/2013)... Ore. For years, Alzheimer,s researchers have focused on ... with Alzheimer,s and may contribute to the disease: plaques ... another protein, called tau. , But for the first ... the two proteins independently, but at the interaction of ... brain tissue of post-mortem Alzheimer,s patients and in mouse ...
(Date:6/19/2013)... 19, 2013 AquaPrint Solutions in Thomson, IL ... Grub with a newly-designed Harley Davidson motorcycle gas tank. A ... Solutions with an idea of taking a split tank motorcycle ... and transforming it into a work of art. , ... Grub several toilet seats that had been dipped in a ...
(Date:6/19/2013)... 19, 2013 The Cancer Support Community ... of cancer care for the whole patient with the ... Cancer Support Community. This inaugural event, held at the ... MD., Ph.D., recognition of Congress members who have made ... of patients and families currently engaged in the cancer ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 North ... PT continuing education course with an online ... therapy assistants and occupational therapists. , ... course supplemented by an online continuing education ... level algorithmic problem solving skills needed to evaluate ...
Breaking Medicine News(10 mins):Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 2Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 3Health News:New Alzheimer's research suggests possible cause: The interaction of proteins in the brain 2Health News:AquaPrint Solutions Transforms Harley Davidson Gas Tank into a Work Of Art for Poopy’s Pub & Grub 2Health News:Keeping the Promise of Cancer Care for the Whole Patient 2Health News:Keeping the Promise of Cancer Care for the Whole Patient 3Health News:New Evidence Based Information on Treatment for Over 8 Million People in the U.S. Affected With Disorders of the Vestibular System 2
... Nursing (NYUCN) received a four-year, $ 2.8M grant from ... and Infectious Diseases (NIH/NIAID) to study "Combination HIV ... is a collaboration between NYUCN, the University of Nairobi, ... Principal Investigator Ann Kurth notes that HIV ...
... FRIDAY, Oct. 28 (HealthDay News) -- Surgery to remove ... as a thyroidectomy, appears to reduce snoring and other ... study. Researchers compared symptoms in patients with obstructive ... a thyroidectomy. Symptoms of obstructive sleep apnea include snoring, ...
... -- In 2008, as part of a larger initiative aimed ... reimbursing for the treatment of injuries related to in-hospital falls. ... could have an unintended negative consequence. In trying to ... that hospitals might discourage patients from moving about at all. ...
... against a whole range of bacterial pathogens, have been ... drugs to treat viral diseases, on the other hand, ... led by Dr. Albrecht von Brunn of LMU Munich ... have identified a compound that inhibits the replication of ...
... than 1.5 billion overweight adults, including 400 million who are obese. ... women and 60 per cent of men are either overweight or ... weight loss, more than 80 per cent of obese dieters fail ... overweight or obese adults, with a BMI of between 27 and ...
... Trying to avoid eating the entire bag of candy bars ... that you won,t have the willpower to resist midnight raids ... be scary for your diet, according to Kara Smith, special ... several tips on how to limit empty Halloween calories, including: ...
Cached Medicine News:Health News:NYUCN receives $2.8 million NIH/NIAID grant to study combination HIV prevention for Kenyan youth 2Health News:Thyroid Surgery Linked to Improved Sleep Apnea Symptoms 2Health News:Study finds no link between elderly patient activity and hospital falls 2Health News:Novel strategy stymies SARS et al. 2Health News:Novel strategy stymies SARS et al. 3Health News:Obese people regain weight after dieting due to hormones 2
Lumicon 48 mm red filter....
Heavy duty, all purpose illuminator available in blue and green. Unique Clip Switch automatically turns off when returned to pocket. Pre-focused lens tip Heine XHL Halogen bulb for bright, concentra...
... A child-friendly vision test ... takes just seconds. Welch ... first objective, accurate vision ... early detection of refractive ...
... is a black and white ... by people who have visual ... control selector, the Classic can ... black text on a white ...
Medicine Products: